CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
Fees for codes L8701 and L8702 are effective as of April 1, 2024 BOSTON (March 1, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for […]
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
BOSTON (February 29, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024. […]
Myomo Closes $6M Registered Direct Offering
BOSTON (January 19, 2024) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing […]
Myomo Announces $6M Registered Direct Offering
BOSTON (January 17, 2024) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of […]
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
BOSTON (January 17, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023. (Read more)
Myomo Reports Q3 2023 Financial Results
Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 7, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical […]
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting
Public Meeting Scheduled for November 29, 2023 BOSTON (November 6, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) posted a proposed Medicare Durable […]
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
Press Release Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category Standard Medicare Part B patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (November 2, 2023) – Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality […]
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (November 2, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that […]
Myomo to Report Third Quarter Financial Results on November 7, 2023
BOSTON (October 31, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023. Read […]